“Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance”. Journal of Cancer Research Updates, vol. 2, no. 4, Nov. 2013, pp.  306-317, https://doi.org/10.6000/1929-2279.2013.02.04.9.